AAT-ADPD 2018 Symposium Chapter I: Chair's Welcome
Chair's welcome to the AAT-ADPD 2018 symposium, including the symposium objectives and agenda
AAT-ADPD 2018 Symposium Chapter II: A multifaceted disease: why we need to tackle AD from all angles
Professor Cummings’ presentation focuses on the complexity of AD at all levels, from genetics through to clinical trials, and introduces the expert faculty and topics presented at the AAT-ADPD 2018 symposium.
AAT-ADPD 2018 Symposium Chapter III: Acting early in AD: giving patients the best chance
Jean Georges presents results from two surveys investigating caregiver experiences of AD diagnosis and public perceptions and awareness of AD and views on the value of diagnosis. Jean Georges discusses the significance of these findings and how they can help to support earlier and more effective diagnosis and care of patients with AD.
AAT-ADPD 2018 Symposium Chapter IV: The biomarker toolbox: changing clinical practice now and for the future
Professor Blennow introduces the core AD CSF biomarkers Aβ42, t-tau and p-tau and efforts to standardise and automate CSF biomarker assays. Professor Blennow also discusses ongoing research into blood-based biomarkers such as Aβ42/40 and neurofilament levels, and how these might be used for patient screening and monitoring therapeutic effects in the future.
AAT-ADPD 2018 Symposium Chapter V: Leading the fight: an exploration of multiple AD targets and better clinical trials
Dr Doody discusses ongoing efforts to optimise the design of Phase 3 clinical trials in early AD to increase the likelihood of successful trials, giving examples of drugs targeting amyloid β and tau. Dr Doody also discusses novel therapeutic approaches in AD including combination therapies and the potential for adapting therapeutic strategies from other disease areas.
AAT-ADPD 2018 Symposium Chapter VI: The future in collaboration: what can be done further for patients with early onset/highest AD risk?
Dr Bateman discusses research in patients with a high risk of AD due to genetic mutations, giving examples of partnerships between public and private sector organisations, such as the DIAN and the Alzheimer’s Prevention Initiative (API). Dr Bateman also presents novel approaches to clinical trials incorporating biomarkers, adaptive trial designs, and efforts towards primary prevention in patients with ADAD.